已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Long-Term Evolocumab in Patients With Established Atherosclerotic Cardiovascular Disease

Evolocumab公司 医学 动脉粥样硬化性心血管疾病 内科学 疾病 心脏病学 期限(时间) 重症监护医学 胆固醇 载脂蛋白B 物理 量子力学 载脂蛋白A1
作者
Michelle L. O’Donoghue,Robert P. Giugliano,Stephen D. Wiviott,Dan Atar,Anthony Keech,Julia Kuder,Canqing Yu,Sabina A. Murphy,Jose H. Flores‐Arredondo,J. Antonio G. López,Mary Elliott‐Davey,Bei Wang,Maria Laura Monsalvo,Siddique Abbasi,Marc S. Sabatine
出处
期刊:Circulation [Lippincott Williams & Wilkins]
卷期号:146 (15): 1109-1119 被引量:247
标识
DOI:10.1161/circulationaha.122.061620
摘要

Background: In FOURIER (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk), the proprotein convertase subtilisin-kexin type 9 inhibitor evolocumab reduced low-density lipoprotein cholesterol (LDL-C) and risk of cardiovascular events and was safe and well tolerated over a median of 2.2 years of follow-up. However, large-scale, long-term data are lacking. Methods: The parent FOURIER trial randomized 27 564 patients with atherosclerotic cardiovascular disease and LDL-C ≥70 mg/dL on statin to evolocumab versus placebo. Patients completing FOURIER at participating sites were eligible to receive evolocumab in 2 open-label extension studies (FOURIER-OLE [FOURIER Open-Label Extension]) in the United States and Europe; primary analyses were pooled across studies. The primary end point was the incidence of adverse events. Lipid values and major adverse cardiovascular events were prospectively collected. Results: A total of 6635 patients were enrolled in FOURIER-OLE (3355 randomized to evolocumab and 3280 to placebo in the parent study). Median follow-up in FOURIER-OLE was 5.0 years; maximum exposure to evolocumab in parent plus FOURIER-OLE was 8.4 years. At 12 weeks in FOURIER-OLE, median LDL-C was 30 mg/dL, and 63.2% of patients achieved LDL-C <40 mg/dL on evolocumab. Incidences of serious adverse events, muscle-related events, new-onset diabetes, hemorrhagic stroke, and neurocognitive events with evolocumab long term did not exceed those for placebo-treated patients during the parent study and did not increase over time. During the FOURIER-OLE follow-up period, patients originally randomized in the parent trial to evolocumab versus placebo had a 15% lower risk of cardiovascular death, myocardial infarction, stroke, or hospitalization for unstable angina or coronary revascularization (hazard ratio, 0.85 [95% CI, 0.75–0.96]; P =0.008); a 20% lower risk of cardiovascular death, myocardial infarction, or stroke (hazard ratio, 0.80 [95% CI, 0.68–0.93]; P =0.003); and a 23% lower risk of cardiovascular death (hazard ratio, 0.77 [95% CI, 0.60–0.99]; P =0.04). Conclusions: Long-term LDL-C lowering with evolocumab was associated with persistently low rates of adverse events for >8 years that did not exceed those observed in the original placebo arm during the parent study and led to further reductions in cardiovascular events compared with delayed treatment initiation. Registration: URL: https://www.clinicaltrials.gov ; Unique identifiers: NCT02867813 and NCT03080935.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
称心元枫发布了新的文献求助10
2秒前
554802336给外向的小海豚的求助进行了留言
3秒前
ding应助ohh采纳,获得10
3秒前
香蕉觅云应助czh采纳,获得10
4秒前
爻解发布了新的文献求助10
5秒前
5秒前
斯文败类应助Gumiano采纳,获得10
6秒前
高大的傲雪给高大的傲雪的求助进行了留言
8秒前
犇骉发布了新的文献求助10
8秒前
快来和姐妹玩完成签到,获得积分10
9秒前
Jasper完成签到,获得积分10
10秒前
10秒前
可莉完成签到 ,获得积分10
11秒前
Hu发布了新的文献求助10
11秒前
爻解完成签到,获得积分10
11秒前
15秒前
15秒前
Hu完成签到,获得积分10
18秒前
yliaoyou完成签到,获得积分10
18秒前
zzzzzz完成签到 ,获得积分10
21秒前
21秒前
22秒前
24秒前
Mars_1108发布了新的文献求助10
27秒前
28秒前
天天快乐应助称心元枫采纳,获得10
31秒前
小智发布了新的文献求助10
31秒前
31秒前
小小杜发布了新的文献求助10
31秒前
33秒前
小二郎应助xxw采纳,获得10
35秒前
36秒前
37秒前
kaka完成签到,获得积分10
37秒前
cjyyy完成签到,获得积分20
37秒前
连难胜完成签到 ,获得积分10
38秒前
俞秋烟完成签到,获得积分10
38秒前
小方发布了新的文献求助10
39秒前
41秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 700
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3976455
求助须知:如何正确求助?哪些是违规求助? 3520548
关于积分的说明 11203850
捐赠科研通 3257210
什么是DOI,文献DOI怎么找? 1798648
邀请新用户注册赠送积分活动 877835
科研通“疑难数据库(出版商)”最低求助积分说明 806539